Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Suggests Preoperational Review Meetings Before Submitting NDAs For Continuous Manufacturing

This article was originally published in The Gold Sheet

Executive Summary

FDA suggests early site visits before submitting NDAs and supplements for continuous manufacturing to smooth over rough patches before pre-approval inspections. Agency also shares some insights on what inspectors will be looking for during PAIs of continuous manufacturing facilities.

You may also be interested in...



Performance-Based Conditions Could Ease Post-Approval Changes For Process Analytical Technologies, Experts Say

Pharmaceutical industry officials are promoting the idea of “marrying” the concepts of performance-based approaches and process analytical technology in the draft ICH Q12 guideline. Embedding this idea in ICH Q12 would give industry more flexibility in managing post-approval changes and aligns with the guideline’s concept of lifecycle improvement.

Pink Sheet Roundtable: Experts Advise On How To Prepare For DSCSA In 2020

2020 is when supply chain partners must agree on a vision for the track-and-trace anticounterfeiting system due in November 2023, experts tell the Pink Sheet.

New Jersey OTC Firm Lacked GMP Basics, FDA Warning Letter Says

US FDA warns that Health Pharma USA was shipping product before its quality unit could review and test it.

Topics

UsernamePublicRestriction

Register

PS000986

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel